Welcome to our dedicated page for Evofem Bioscienc SEC filings (Ticker: EVFM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Evofem Biosciences’ dense disclosures can feel like a clinical trial on your patience. Whether you’re hunting for Phexxi sales milestones or future pipeline costs, locating the right note inside a 300-page filing is tough. Investors often type “Evofem Biosciences SEC filings explained simply” hoping for clarity. Stock Titan delivers that clarity with AI-powered context so you can focus on decisions, not document navigation.
Our platform ingests every new submission to EDGAR and delivers instant, plain-English takeaways. Stock Titan offers comprehensive coverage of all filing types with real-time updates. Within minutes you’ll know how cash burn shifted in the latest Evofem Biosciences quarterly earnings report 10-Q filing or spot red flags in an 8-K. Key features include:
- Real-time alerts for Evofem Biosciences Form 4 insider transactions real-time so you never miss meaningful trade activity.
- Side-by-side visuals comparing R&D spend across periods for deeper Evofem Biosciences earnings report filing analysis.
- Concise overviews that make the Evofem Biosciences annual report 10-K simplified enough for a quick read yet rich enough for due diligence.
- One-click drill-downs that turn mysterious line items into actionable data—perfect for Evofem Biosciences 8-K material events explained.
Need to monitor governance? Our AI highlights option grants and pay ratios within the Evofem Biosciences proxy statement executive compensation and flags unusual activity in Evofem Biosciences insider trading Form 4 transactions. That combination means understanding Evofem Biosciences SEC documents with AI becomes part of your routine workflow. Whether you’re tracking Evofem Biosciences executive stock transactions Form 4 ahead of catalysts or benchmarking margins, Stock Titan turns raw filings into insight—saving hours and sharpening your investment thesis.
Evofem Biosciences (EVFM) terminated its merger agreement with Aditxt effective October 20, 2025, after stockholders did not approve the transaction. The company exercised its contractual right to terminate based on the merger’s outside date and the failure to obtain Company Shareholder Approval. All related ancillary agreements ended concurrently, except for the existing non‑disclosure agreement. No consideration was paid in connection with the termination.
At the October 20 special meeting, quorum was reached with 100,494,436 votes represented out of 256,360,511 eligible votes. Proposal 1 to approve the merger received 93,239,872 votes for, 7,208,466 against, and 46,097 withheld, and was not approved. Proposal 2, authorizing potential adjournment, passed with 97,435,999 for, 2,840,322 against, and 218,115 withheld.
The company cautioned that termination could affect operations and relationships and referenced risks including potential costs and obligations described in its risk disclosures.
Evofem Biosciences (EVFM) entered a third amendment to its Securities Purchase Agreement with Adjuvant on October 13, 2025. The amendment updates when the related convertible notes become payable in full to the earlier of six months after the Effective Date, at Adjuvant’s election upon a Change of Control, or the date of any acceleration under Section 8.
The notes may not be prepaid before the date that is six months after the Effective Date without Adjuvant’s prior written consent. This sets a defined near‑term timeline for potential repayment while limiting early prepayment.
FAQ
What is the current stock price of Evofem Bioscienc (EVFM)?
What is the market cap of Evofem Bioscienc (EVFM)?
